Clinical Trial Update: A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma [Phase 3]

View source ↗

Summary

A phase 3 trial comparing carfilzomib to best supportive care in relapsed and refractory multiple myeloma has completed and posted results in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Kyprolis (carfilzomib)

Snippet

Sponsor: Amgen | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED | Results posted: 2015-08-04